INTRODUCTION
The pancreas is a unique organ that has both exocrine and endocrine compartments.
Pancreatic cancer is the fourth leading cause of cancer-related death in US, with a 5-year survival rate less than 6%. More than 90% of pancreatic cancers arise from the exocrine portion of the pancreas and are pancreatic ductal adenocarcinomas. Due to lack of early cancer-related symptoms, patients with pancreatic cancer are often diagnosed at an advanced stage (1, 2) .
Gemcitabine, a deoxycytidine analogue, is the standard chemotherapy treatment for advanced pancreatic cancer. Gemcitabine can directly incorporate into DNA or inhibit ribonucleotide reductase to prevent DNA replication and, thus, tumor cell growth (3) . However, almost all patients have either primary or eventually gain secondary resistance to gemcitabine treatment.
The major causes for resistance can be summarized into three aspects: failure of gemcitabine uptake through hENT1 transporter, decrease of effective drug dose by enzyme metabolism, and gain of resistance to cellular stresses or apoptosis. Because of potential improved cytotoxicity, several combination therapies of gemcitabine plus additional agents are being tested in clinical trials. So far gemcitabine with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, is the only FDA-approved combination treatment. This regimen has a modest effect, which can prolong median overall survival for less than 2 weeks (4). Thus, understanding the molecular events that occur during the development of gemcitabine resistance will lead to improvement of pancreatic cancer treatments.
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4 Polo-like kinase 1 (Plk1) is a well-studied serine and threonine protein kinase. It plays important roles in cell proliferation, such as mitotic entry, centrosome maturation, kinetochoremicrotubule attachment, chromosome segregation and cellular checkpoint adaptation (5) (6) (7) (8) (9) (10) (11) (12) .
Although evidence of Plk1 as an oncogene is scarce, it is overexpressed in various tumors. And the level of Plk1 correlates with poor prognosis of cancer patients (13) . Inhibition of Plk1 induces mitotic arrest, followed by cell death in cancer cells, but not in normal cells (14) . A recent study suggests that Plk1 might be a mediator for gemcitabine resistance in pancreatic cancer. Among nearly forty potential target genes, Plk1 was the only gene that distinguished gemcitabine-sensitive versus -resistant tumors (15) . Our previous work indicates that Plk1 phosphorylates Origin Recognition Complex 2 (Orc2) to promote DNA replication under replication stress such as the one induced by gemcitabine treatment (16). We also reported that Plk1 regulates pre-replication complex (pre-RC) formation through phosphorylation of histone acetyltransferase binding to the Orc1 (Hbo1) (17) . Therefore, we hypothesize that Plk1-associated kinase activity towards Orc2 and Hbo1 drives DNA replication in the presence of gemcitabine, eventually contributing to development of gemcitabine resistance in pancreatic cancer.
To test our central hypothesis, we first investigated the correlation between Plk1 expression and gemcitabine resistance with a combination of different pancreatic cell lines, xenograft mice and pancreatic cancer patient tissues. Our data suggest that Plk1 overexpression correlates with gemcitabine resistance in pancreatic cancer cells and xenograft tumors. Inhibition of Plk1
Plk1 in gemcitabine resistance 5 activity significantly enhances the antitumor effect of gemcitabine in a Panc-1 xenograft model. Mechanistically, we found that Plk1 phosphorylation of Orc2 at the origin of DNA replication is increased upon gemcitabine treatment, and that cells expressing a Plk1-unphosphorylatable mutant of Orc2 are more sensitive to gemcitabine treatment. Surprisingly, gemcitabine treatment decreases Hbo1 at the replication origin but recruits it to the promoter of cFos, an AP-1 transcription factor. We further show that Hbo1 phosphorylation by Plk1 up-regulates the transcriptional expression of cFos, consequently resulting in an elevation of its target Multi Drug Resistance 1 (MDR1). Knockdown of cFos or MDR1 sensitizes gemcitabine-resistant cells to gemcitabine treatment. Taken together, our findings define an important signaling pathway of gemcitabine resistance in pancreatic cancer, suggesting a novel strategy to treat gemcitabine-resistant pancreatic cancer.
MATERIALS AND METHODS

Chemicals
BI 2536 was purchased from Symansis NZ Ltd, New Zealand. Gemcitabine (Cat.
3259) was purchased from Tocris Bioscience, USA ( Figure 2C, 2D ).
Mouse xenograft model
Panc-1 cells (5×10 6 cells/mouse) were mixed with an equal volume of Matrigel (Collaborative Biomedical Products) and inoculated into the right flank of athymic nude mice (Harlan Laboratories). One week later, the animals were randomized into Plk1 in gemcitabine resistance 6 treatment and control groups of five mice each. BI 2536 was dissolved in 0.1N HCl, diluted with 0.9% NaCl, and injected into the tail vein twice weekly for 6 weeks. Gemcitabine was dissolved in 0.9% NaCl, and diluted with 0.9% NaCl, and injected into the tail vein twice weekly for 6
weeks. Tumor volumes, estimated from the formula: V = L×W 2 /2 (V, mm 3 ; L, mm; W, mm),
were measured every other day with digital calipers.
Statistical analysis A standard two-tailed unpaired student t test was used to calculate differences between samples. One-way analysis of variance was used to determine statistically significant differences from the mean in the xenograft study.
Cell culture, transfection, and RNAi The Panc-1 and BxPC-3 cells were purchased from American Type Culture Collection. Cells were initially grown and multiple aliquots were stored at -180°C for future use as required. Cells were purchased more than 6 months ago and were not further tested or authenticated by the authors. Panc-1 cells were cultured in Dulbecco modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum, 100 units/ml penicillin, and 100 units/ml streptomycin at 37℃ in 5% CO 2 . BxPC-3 cells were cultured in RPMI-1640 medium. HPDE6 cells were cultured in keratinocyte medium (Invitrogen). Plasmid DNA was transfected with MegaTran (Origene) as described by the manufacturer. The cFos (sc-29221) and MDR1 (sc-29395) siRNAs were purchased from Santa Cruz Biotechnology and transfected with Oligofectamine (Invitrogen) as described by the manufacturer.
Western blotting
After cells were lysed in AMI lysis buffer (Active Motif), proteins were detected by Western blotting with antibodies against Plk1 (Santa Cruz, sc-17783), β-actin (Sigma, A5441), and PARP (Millipore AB3565).
Immunohistochemistry (IHC)
After murine or human paraffin-embedded slides were deparaffinized and rehydrated, antigens were retrieved in antigen unmasking solution (Vector Laboratories) with a 2100-Retriever (PickCell Laboratories). Samples were then incubated with primary antibodies against Plk1 (Upstate, 08544) and Ki67 (Abcam, ab16667) or subjected to TUNEL assay (Roche, 11684817910).
Cell viability assay Cells were grown in 96-well plates, and viable cell numbers were determined with the CellTiter-Glo Luminescent Cell Viability Assay kit (Promega) as described by the manufacturer.
Combination index IC50 and combination index of gemcitabine and BI 2536 were calculated as indicated in (18) . Combination index > 1 indicates antagonism; combination index < 1 indicates synergy; and combination index = 1 indicates an additive effect.
BrdU labeling assay BrdU-labeling assays were performed with a kit from Roche (Cat.11170376001) according to the manufacturer's instructions.
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Details of Isolation of cells from xenograft tumors, Chromatin immunoprecipitation and
Quantitative real-time PCR analysis are described in supplemental information. (Table S1 ).
RESULTS
Plk1 is overexpressed in pancreatic tumors
To determine whether the sensitivity to gemcitabine is influenced by Plk1 activity, we measured the combination index of gemcitabine and BI 2536 (an ATP competitive inhibitor which specifically inhibits Plk1 kinase activity) as described in the material and method ( Figure   2C and 2D). The IC50 value of gemcitabine for Panc-1 cells was 1284 nM (Table 1) . However, the IC50 of gemcitabine was reduced to 44 nM when the cells were treated in combination with 2 nM BI 2536. The combination index was calculated to be 0.3 (Table 1) , which is less than 1, suggesting a synergistic effect between gemcitabine and BI 2536. protein levels show any obvious differences among these tumors, so it is unlikely that gemcitabine resistance is more related to the protein levels of the Orc2 and Hbo1 ( Figure 2I ).
More importantly, to assess the significance of this correlation, we quantified the Plk1 protein levels ( Figure 2I ), and measured the correlation efficiency between Plk1 expression signal tumors were used to generate the sublines, eight sublines were generated. As shown in Figure   4A , consistent with our previous observations, the gemcitabine-sensitive tumors (#6) had a lower level of Plk1. Interestingly, the p-Orc2 level increased 3-fold for tumor #19 compared to staining (Histone H3 is specifically phosphorylated at Ser10 during mitosis which can be served as a mitotic marker) and FACS analysis ( Figure S2G and S2H). These analyses support the notion that Plk1 confers the gemcitabine resistance of pancreatic cancer.
Plk1 phosphorylation of Orc2 promotes DNA replication in the presence of gemcitabine Next, we dissected the mechanism for Plk1-associated gemcitabine resistance in pancreatic cancer.
Orc2 is a key component of the pre-RC complex, which plays important roles in initiation of DNA replication (19) . We recently reported that Plk1 phosphorylation of Orc2 promotes DNA replication under various stress conditions (16). Because gemcitabine-resistant pancreatic tumors have elevated Orc2 phosphorylation, we hypothesize that Plk1 phosphorylation of Orc2 is a driving force for cell proliferation in the presence of gemcitabine in pancreatic cancer.
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We first asked whether Plk1-mediated Orc2 phosphorylation is enhanced at the replication origin by the DNA replication stress induced by gemcitabine. Towards this end, we performed chromatin immunoprecipitation (ChIP) experiments with antibodies against Orc2 and p-Orc2, and examined the well-defined Orc2-associated DNA replication origin (MCM4). As shown in Figure 5A , we were able to detect the signal by Orc2 antibody on the MCM4 origin (about 500 further confirm this notion, we examined cell death in these two populations upon gemcitabine treatment. Cells expressing the Orc2-A mutant showed increased cell death compared to cells expressing Orc2-WT, suggesting that Plk1 phosphorylation of Orc2 is indeed one mechanism for increased gemcitabine resistance in pancreatic cancer ( Figure 5C ).
Plk1 phosphorylation of Hbo1 increases cFos, consequently elevating its target, MDR1
Hbo1, the enzyme responsible for histone H4 acetylation, is a core subunit of a protein complex comprised of JADE1/2/3 paralogs, hEaf6 and ING5. This complex interacts with the Mcm helicase and is essential for DNA replication to occur during S phase (20) . Recently, it was reported that Hbo1 is recruited to the promoter of AP-1 and serves as a co-activator to increase AP-1 transcription in response to environmental stress (21) . More importantly, the expression level of Hbo1 is high in various human carcinomas (22) . Previous studies in our lab demonstrated that Plk1 phosphorylation of Hbo1 positively regulates its acetylation activity to promote DNA replication (17) . Given these facts, we next asked whether Plk1 phosphorylation of Hbo1 also contributes to gemcitabine resistance in pancreatic cancer.
To test this hypothesis, we first performed BrdU-labeling assays with cells expressing Hbo1-WT or Hbo1-A mutant (Plk1 unphosphorylatable mutant, S57A) ( Figure S3B ). As shown in Figure   S3C , cells expressing Hbo1-A are more sensitive to gemcitabine treatment as compared with cells expressing Hbo1-WT. As a result of this sensitivity, cells expressing Hbo1-A showed increased cell death as indicated by an increased cleaved-PARP protein level after gemcitabine Plk1 in gemcitabine resistance 16 treatment ( Figure S3D ). These data suggest that Plk1 phosphorylation of Hbo1 also plays a role in gemcitabine resistance of pancreatic cancer.
To dissect the mechanism of this observation, we first examined the occupancy of endogenous Hbo1 at the replication origin upon gemcitabine treatment by ChIP analysis. To our surprise, Hbo1 was significantly decreased from the replication origin after gemcitabine treatment ( Figure S3E ). Instead, we observed that Hbo1 accumulated at the promoter of cFos ( Figure 6A ), an AP-1 transcription factor. This observation is consistent with the previous report that Hbo1 is recruited at the cFos promoter site to serve as a transcriptional co-activator upon stress (21) . So it is possible that Hbo1 at the cFos promoter activates cFos gene transcription. As the induction of cFos by therapeutic drug treatment is involved in the acquisition of drug resistance (23-25),
we then examined whether cFos transcription is induced by gemcitabine treatment. As shown in Figure 6B , the expression level of cFos was increased by 2. To test whether the elevated cFos contributes to gemcitabine resistance in pancreatic cancer, we next examined its transcriptional target, multi-drug resistance 1(MDR1), as MDR1 has been reported to mediate drug resistance by exporting drugs out of cells (24, 26, 27) . Consistent with the results in Figure 6C , we observed that overexpression of Hbo1-WT, but not Hbo1-A, also amplified the induction of MDR1 (3-fold) upon gemcitabine treatment ( Figure 6D) . Moreover, 
DISCUSSION
Gemcitabine is the current standard chemotherapy for pancreatic cancer, a deadly disease.
However, only 30% of patients benefit from this agent, and among those, almost all will become resistant usually within 3-4 months. In this study, we have investigated the putative mechanisms of gemcitabine resistance in pancreatic tumors. We found that Plk1 Increased phosphorylation of Orc2 at the replication origin upon gemcitabine treatment maintains DNA replication for cell survival ( Figure 5A, B) . As a consequence, pancreatic cancer cells expressing the Plk1-unphosphorylatable mutant of Orc2 became more sensitive to gemcitabine treatment ( Figure 5C ), suggesting that Plk1-mediated phosphorylation of Orc2 is one mechanism that contributes to gemcitabine resistance of pancreatic cancer.
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We acknowledge that Plk1 likely regulates cellular responses to gemcitabine treatment via multiple mechanisms. We also reported previously that Hbo1 is phosphorylated by Plk1 to regulate DNA replication (17) . To our surprise, we observed a decrease of Hbo1 at the replication origin upon gemcitabine treatment ( Figure S3E ). Instead, Hbo1 accumulated at the promoter region of cFos, an AP-1 transcription factor ( Figure 6A ), which is consistent with the recent report of Hbo1 recruitment to the AP-1 promoter under environmental stress and the overall role of Hbo1 in regulating the p53 pathway (21, 28) . These observations suggest that
Hbo1 might contribute to gemcitabine resistance independent of its role in DNA replication. To support this notion, we found that cFos and its target MDR1 were significantly induced by gemcitabine treatment in a manner dependent on Plk1 phosphorylation of Hbo1 ( Figure 6B-D) .
The elevation of cFos transcription is likely due to the accumulation of Hbo1 at the cFos promoter upon gemcitabine treatment ( Figure 6A ). In the gemcitabine-resistant Panc-1 cells that we isolated from xenograft tumors, both cFos and MDR1 expression were elevated ( Figure   6E , F). Significantly, knock-down of cFos or MDR1 sensitizes these gemcitabine-resistant cells to gemcitabine treatment. Additional genes in the p53 pathway that are regulated by Hbo1 may also have a role in gemcitabine resistance but our data support one mechanism of Hbo1-mediated resistance in which overexpressed Plk1 in pancreatic tumors phosphorylates Hbo1 to elevate cFos and its target MDR1, eventually contributing to gemcitabine resistance.
Combining these results with the data of Orc2 described above, we propose a model that Plk1
phosphorylates Orc2 and Hbo1 to mediate gemcitabine resistance in pancreatic cancer. As transfected with Flag-Hbo1-A, GFP-Orc2-A, or both, and treated with or without gemcitabine (50nM) for 24h, and subjected by western blots.
